Business Context and Reporting Period
Inogen, Inc. (INGN) is a medical technology company focused on respiratory products, including portable oxygen concentrators, airway clearance devices, and CPAP masks. The company operates as both a manufacturer and a home medical equipment provider. This summary covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $85.1 million | $82.3 million |
| Net Loss | $(8.3) million | $(6.2) million |
| Diluted Net Loss Per Share | $(0.30) | $(0.25) |
| Gross Margin (Total) | 44.5% | 44.2% |
| Cash and Cash Equivalents | $93.1 million | $118.9 million (Q1 2025) |
| Net Cash Used in Operating Activities | $(6.7) million | $(16.8) million |
| Adjusted EBITDA (Non-GAAP) | $(1.4) million | $0.036 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3.4% year-over-year. Sales revenue grew 5.7% to $72.4 million, driven by a 14.0% increase in oxygen system unit sales (approx. 49,000 units vs. 43,000 units) and strong international demand. Conversely, rental revenue declined 8.0% to $12.7 million due to fewer patients on service.
- Geographic Mix: International sales increased 17.8% to $37.7 million, while U.S. sales decreased 4.8% to $34.7 million. Europe accounted for 89.1% of international sales.
- Operating Expenses: Total operating expenses rose to $47.2 million (up 7.2%). Research and Development (R&D) increased 26.4% due to new product investments. General and Administrative (G&A) expenses increased 7.8%, primarily due to $0.9 million in restructuring-related costs.
- Profitability: Net loss widened by 34.8% to $8.3 million, primarily driven by increased operating expenses. Gross margin on sales improved slightly to 44.5% due to manufacturing leverage and lower semiconductor costs.
Outlook, Risks, and Unusual Items
- Share Repurchase Program: In February 2026, the Board authorized a $30.0 million share repurchase program. During Q1 2026, the company repurchased 298,100 shares for approximately $1.9 million. Approximately $28.1 million remains available under the program.
- Liquidity: Management believes current cash, cash equivalents, and marketable securities are sufficient to meet operating and investing requirements for at least the next 12 months. However, the company may need to raise additional funds for future growth.
- Risks: Key risks include supply chain constraints, inflationary pressures on raw materials, foreign currency fluctuations, and changes in government reimbursement rates (Medicare/Medicaid). The company noted no material changes to risk factors from the 2025 10-K, aside from the new share repurchase program.
- Unusual Items: The quarter included $0.9 million in restructuring-related charges and $0.2 million in stockholder engagement and proxy defense costs, which were excluded from Adjusted EBITDA.
Investor Verification Checklist
- Verify the sustainability of the 17.8% growth in international sales and the impact of foreign exchange rates on future margins.
- Monitor the trend in rental revenue and the number of patients on service, as this segment declined 8.0%.
- Assess the impact of the new $30 million share repurchase program on future liquidity and capital allocation.
- Review the trajectory of R&D spending (up 26.4%) and the timeline for new product commercialization.
- Confirm the status of reimbursement rates for Medicare and Medicaid, which accounted for 62.6% of rental revenue.